Danuglipron (PF-06882961): Pfizer's Discontinued Oral GLP-1 Agonist — Research Profile and Lessons Learned

# Danuglipron (PF-06882961): Pfizer's Discontinued Oral GLP-1 Agonist — Research Profile and Lessons Learned

Disclaimer: This article is for research and educational purposes only. Danuglipron is a discontinued investigational compound that never received FDA approval. This profile is intended for researchers and clinicians studying oral GLP-1 pharmacology and the factors contributing to clinical program outcomes.

---06882961, was Pfizer's investigational oral small-molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA). Developed as Pfizer's entry into the competitive obesity and type 2 diabetes pharmacotherapy market, danuglipron showed meaningful efficacy in Phase 2 clinical trials but was ultimately discontinued in April 2025 — first due to high gastrointestinal adverse event rates and patient discontinuation with twice-daily dosing, and finally following the emergence of a drug-induced liver injury (DILI) signal in the once-daily dose optimization program.

The story of danuglipron is not simply a failure narrative. It is a scientifically rich case study in the challenges of translating GLP-1 receptor pharmacology into an oral small-molecule drug — a case that informed the development of competing programs and provided mechanistic insights relevant to the broader oral incretin field.

---1 Strategy

By the early 2020s, the commercial success of injectable GLP-1 agonists — semaglutide's STEP trials, tirzepatide's SURMOUNT program — had made clear that obesity pharmacotherapy was transforming. The multi-hundred-billion-dollar injectable GLP-1 market created enormous incentive for an oral alternative.

Pfizer developed danuglipron alongside a distinct oral formulation approach: unlike Novo Nordisk's Rybelsus (which modified the peptide semaglutide for limited GI absorption), Pfizer pursued a fully synthetic small-molecule agonist — conceptually similar to Eli Lilly's orforglipron but with a different chemical scaffold and initially a twice-daily (BID) dosing regimen.

---peptide, small-molecule GLP-1 receptor agonist** that binds to the transmembrane domain of the GLP-1R, inducing receptor activation independently of the native GLP-1 peptide ligand. Like orforglipron and other small-molecule GLP-1R agonists, danuglipron:

• •Activates Gs-cAMP-PKA downstream signaling
• •Produces glucose-dependent insulin secretion (low hypoglycemia risk)
• •Reduces appetite via hypothalamic and brainstem GLP-1R activation
• •Slows gastric emptying
• •Suppresses postprandial glucagon release

The fundamental pharmacology of danuglipron at the GLP-1R is comparable to other agents in the class. Where danuglipron diverged was in its pharmacokinetic profile and hepatic metabolism, which ultimately proved clinically problematic.

Structural note: The chemical scaffold of danuglipron differs from orforglipron. Structurally, small-molecule GLP-1R agonists tend to engage a transmembrane binding cavity; the specific scaffold influences metabolic liability (CYP enzyme interactions), GI distribution (absorption site, local concentration effects on enterochromaffin cells), and potentially off-target activity. The exact structural basis for danuglipron's liver injury signal remains under investigation by researchers.

--- Dose-dependent placebo-adjusted reductions in HbA1c: up to −1.16 percentage points

• •Fasting plasma glucose reduction: −33.24 mg/dL
• •Body weight reduction: −4.17 kg over 16 weeks
• •Safety: predominantly GI adverse events (nausea, vomiting), consistent with GLP-1 class

These results established proof-of-concept for small-molecule GLP-1R agonism in T2D and supported progression to the obesity program.

Phase 2b Obesity Trial (NCT04707313) — December 2023

Design: Phase 2b, randomized, double-blind, placebo-controlled trial in adults with obesity without T2D. Multiple twice-daily doses evaluated over 32 weeks.

Primary endpoint: Change in body weight from baseline.

Efficacy results:

• •The trial met its primary endpoint, with statistically significant weight reductions across all danuglipron doses
• •Placebo-adjusted mean weight reductions ranged from −8% to −13% at 32 weeks
• •At 26 weeks, placebo-adjusted reductions of −5% to −9.5%
• •All doses significantly outperformed placebo on the primary endpoint

These were genuinely impressive results — particularly the upper end of 13% placebo-adjusted weight loss, which is competitive with what injectable GLP-1 agents achieve in shorter trials.

The problem:

GI tolerability was poor. Nausea occurred in up to 73% of participants, vomiting in up to 47%, and diarrhea in up to 25%. These rates — while consistent with GLP-1 class pharmacology — were dramatically higher than rates observed with injectable semaglutide or tirzepatide at equivalent efficacy doses.

Discontinuation rates were high. More than 50% of participants discontinued treatment across all doses, compared to approximately 40% with placebo. This discontinuation rate exceeded what is observed with most approved GLP-1 therapies and raised serious concerns about real-world tolerability.

---Daily Dosing

Following the Phase 2b results, Pfizer made a strategic pivot: rather than continuing with the twice-daily formulation, the company developed a modified once-daily (QD) formulation of danuglipron, hypothesizing that a longer-acting formulation would smooth the plasma concentration-time profile and reduce peak GI exposure — potentially improving tolerability while maintaining efficacy.

Two dose-optimization studies (NCT06567327 and NCT06568731) were initiated to evaluate multiple doses of the once-daily modified formulation.

The dose-optimization studies achieved key pharmacokinetic objectives, confirming a once-daily formulation and dose with potential for competitive efficacy and tolerability profiles based on earlier twice-daily danuglipron data.

---Induced Liver Injury (April 2025)

Despite promising PK results from the once-daily formulation, Pfizer announced the complete discontinuation of the danuglipron clinical program in April 2025, following the observation of a potential drug-induced liver injury (DILI) case.

What happened:

A single asymptomatic participant in one of the once-daily dose-optimization studies experienced potential drug-induced liver injury — specifically, elevated liver enzymes (transaminases) suggesting hepatocellular damage — which resolved following drug discontinuation.

Context:

• •Pfizer noted that the overall frequency of liver enzyme elevations across the entire danuglipron safety database (>1,400 participants) was "in-line with approved agents in the class"
• •The single DILI case was asymptomatic (no jaundice, no symptoms)
• •However, DILI signals — even single cases — carry special regulatory significance; the FDA and international regulatory agencies have strict thresholds for hepatotoxicity signals in otherwise healthy populations

Why did Pfizer stop?

The decision combined the DILI signal with regulatory feedback. Per Pfizer's statement: "the overall clinical profile, combined with regulatory feedback, led the company to end the program." The regulatory interaction suggests the FDA's concern about the liver signal — even if statistically rare — was sufficient to make a path to approval unfeasible.

Was it Hy's Law? A single case of elevated aminotransferases (without bilirubin elevation meeting Hy's Law criteria) would normally require careful monitoring but not immediate discontinuation. Pfizer did not characterize the case as meeting Hy's Law criteria. However, the combination of an unresolved safety concern in a healthy population (obesity without serious comorbidities) and the prior tolerability challenges created an unfavorable risk-benefit calculation.

---|---|

---|---|---|

Key differences:

1. Dosing frequency: BID dosing creates twice-daily plasma peaks, potentially leading to higher peak GI receptor stimulation than QD dosing

2. Chemical scaffold: Different structural backbones → different metabolic liability and off-target effects

3. Hepatic metabolism: The DILI signal with danuglipron (absent from orforglipron) likely reflects scaffold-specific CYP metabolite toxicity or reactive metabolite generation — an area of active investigation

---1 receptor is expressed in the GI tract, meaning local GI drug concentration — not just plasma exposure — drives nausea and vomiting. Twice-daily dosing creates twice-daily GI exposure peaks. Extended-release or once-daily formulations that avoid high local GI peak concentrations may be critical for tolerability.

2. Chemical scaffold matters enormously for hepatic safety. Small-molecule GLP-1R agonists share a pharmacological mechanism but can have radically different metabolic fates in the liver. Reactive metabolite formation, CYP induction, and mitochondrial toxicity are scaffold-dependent properties that cannot be predicted from GLP-1R binding affinity alone.

3. Efficacy alone is insufficient. Danuglipron demonstrated 8–13% weight loss (placebo-adjusted) — genuinely impressive efficacy. But efficacy is necessary, not sufficient, when 50%+ of trial participants discontinue and a hepatotoxicity signal emerges.

4. Regulatory DILI thresholds in obesity are strict. In an obesity indication — a large, otherwise relatively healthy population with multiple therapeutic alternatives — the FDA applies a strict safety threshold. A DILI signal that might be tolerable in a disease with fewer alternatives (e.g., advanced liver disease) effectively ends a program in a condition with growing treatment options.

5. The oral GLP-1 concept is pharmacologically valid. Danuglipron's Phase 2 efficacy data — like orforglipron's — confirmed that small-molecule GLP-1R agonists can produce clinically meaningful weight loss. The failure was not conceptual; it was compound-specific.

---1?

Following the discontinuation of danuglipron, the primary validated oral small-molecule GLP-1R agonist is orforglipron (Lilly/Foundayo). Other companies have compounds in earlier stages, including:

• •Novo Nordisk: Pursuing next-generation oral GLP-1 formulations and the distinct oral co-agonist amycretin (amylin + GLP-1)
• •Zealand Pharma / others: Various small-molecule GLP-1R programs in preclinical and early clinical stages

Researchers interested in oral GLP-1 pharmacology should also note that structural biology advances — particularly cryo-EM structures of GLP-1R in complex with small-molecule agonists — are rapidly improving the rational design of compounds that may avoid the tolerability and hepatic safety issues observed with danuglipron.

---06882961) demonstrated meaningful GLP-1 receptor agonism and clinically significant weight loss in Phase 2 clinical trials, validating the small-molecule approach to oral GLP-1 receptor pharmacology. However, its development was ultimately terminated by two compounding challenges: high GI adverse event rates and patient discontinuation with twice-daily dosing, followed by a drug-induced liver injury signal in the once-daily dose-optimization program. Pfizer discontinued the full clinical program in April 2025.

For researchers, danuglipron's clinical journey provides essential lessons in small-molecule GPCR drug design, GI tolerability optimization, hepatic safety assessment, and the strict regulatory standards applied to obesity pharmacotherapy. Its story is inseparable from the broader narrative of the oral GLP-1 revolution — a revolution that ultimately succeeded with orforglipron's FDA approval in April 2026.

---06882961) Phase 2 T2D study. JAMA Network Open (2022). doi: 10.1001/jamanetworkopen.2022.xxxx

2. Pfizer press release: Phase 2b topline results in obesity (December 2023). NCT04707313

3. Pfizer press release: Update on oral GLP-1 receptor agonist danuglipron (April 2025) — program discontinuation

4. Gastroenterology Advisor: "Danuglipron Clinical Program for Chronic Weight Management Discontinued" (2025)

5. Managed Healthcare Executive: "Liver Injury Ends Development of Pfizer's Oral GLP-1 for Obesity" (2025)

6. Drug Discovery World: "Pfizer discontinues oral GLP-1 receptor agonist danuglipron" (2025)

This article is for educational and research purposes only. Danuglipron is a discontinued investigational compound not approved for any indication.

---\n\n## Research References\n\nDanuglipron and GLP-1 receptor research:\n\n- PMID 42601876: GLP-1 receptor agonist mechanism and pharmacodynamics.\n- PMID 42591359: Oral GLP-1 receptor agonist clinical applications.\n- PMID 39002641: Danuglipron and GLP-1 signaling in clinical development.\n-1 receptor research:

• •PMID 42601876: GLP-1 receptor agonist mechanism and pharmacodynamics.
• •PMID 42591359: Oral GLP-1 receptor agonist clinical applications.

---1 receptor research:

• •PMID 42601876: GLP-1 receptor agonist mechanism and pharmacodynamics.
• •PMID 42591359: Oral GLP-1 receptor agonist clinical applications.